Dongwha Pharm "Acquisition of Celltrion OTC Drugs Including Hwaituben"
Dongwha Pharm announced on the 18th that it has acquired four over-the-counter drugs from Celltrion.
The acquired items are Celltrion's cold remedy 'Hwaituben', decongestant 'Hwaituben Nasal Spray', stomatitis treatment 'Albochil', and vitamin D and calcium supplement 'Calcium Chew' sold in Hong Kong and Taiwan.
With this acquisition, Dongwha Pharm expects to lead the cold medicine and stomatitis treatment markets along with its liquid cold remedy 'Pancol'.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
A Dongwha Pharm official said, "As a company leading the domestic over-the-counter drug market, we expect this acquisition to create significant synergy in diversifying our product portfolio and boosting domestic and overseas sales," adding, "We will also do our best to secure growth momentum for our existing over-the-counter drug business along with the business diversification strategy that Dongwha Pharm is pursuing."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
